Clinical Trial Update: Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study [Phase 3]

View source ↗

Summary

Results from an open-label extension of a Phase 3 trial investigated teprotumumab for Graves' orbitopathy (thyroid eye disease) to determine if proptosis reduct…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Orbitopathy

Drugs mentioned

• TEPEZZA (teprotumumab)

Snippet

Sponsor: Amgen | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-07-19